MedImmune will lead a panel discussion at the 2010 BIO International Convention entitled, “A Diamond in the Rough – Trends and Strategies in the Healthcare VC Market,” which will take a deep dive into  current and future trends surrounding traditional and non-traditional investment funding including:

• How VC investment strategies will evolve considering the recent healthcare legislation
• The impact of the recession and drought in IPOs on VC funding and why VC funding in the biotech industry is less susceptible to the pitfalls of a financial slowdown
• Venture capitalists’ investment criteria and how it is shaped during economic cycles
• The increasing hands-on approach of VC firms and what VCs look for when they invest in a start-up company
• Opportunities for life science entrepreneurs within this changing market and the secrets of raising cash in a buyers market

WHO:                   

MedImmune’s Eva Jack, Managing Director of MedImmune Ventures, Inc, will lead the roundtable panel discussion with participants to include:

• Steven Elms, MBA, Managing Partner, Aisling Capital LLC
• Allan Marchington, PhD, Partner, Apposite Capital
• Carole Nuechterlein, Head of Roche Venture Fund  for F. Hoffmann – La Roche Ltd
• Joseph Regan  VP Investments: Life Sciences for GrowthWorks Capital

WHY:                   

With the current recession and lack of IPOs in the market, venture capital investment impacts every non-public biotech company.

WHEN:                

Tuesday, May 4^th
4:00PM to 5:30PM

WHERE:               

Room: S405B, McCormick Place
2301 S. Lake Shore Drive
Chicago, IL  60616

*Please note this panel takes place in a different room from other BIO finance track sessions